Cite
MLA Citation
D. Bergeat et al.. “LOXL2 is a prognosis biomarker and a potential therapeutic target in intrahepatic cholangiocarcinoma.” HPB, vol. 18, n.d., pp. e863–. http://access.bl.uk/ark:/81055/vdc_100055919842.0x000009
This is an interim version of our Electronic Legal Deposit Catalogue-eJournals and eBooks while we continue to recover from a cyber-attack.
D. Bergeat et al.. “LOXL2 is a prognosis biomarker and a potential therapeutic target in intrahepatic cholangiocarcinoma.” HPB, vol. 18, n.d., pp. e863–. http://access.bl.uk/ark:/81055/vdc_100055919842.0x000009